

TENTH ANNUAL

# Markesbery Symposium on Aging and Dementia

Community Session October 31st, 2020

- 9:55 am**                    **Join meeting via Zoom link**
- 10:00 am**                    **Welcome**
- Linda Van Eldik, PhD *Director, Sanders-Brown Center on Aging & Alzheimer's Disease Research Center, University of Kentucky*
- 10:05 am**                    **Keynote Speaker**
- Advancing the Science: The Latest in Alzheimer's and Dementia Research**  
Maria Carrillo, PhD *Chief Science Officer, National Alzheimer's Association*
- 10:50 am**                    **Break**
- 11:00 am**                    **My Medications and Why Should I Know about Them**
- Daniel Moga, MD, PhD *Associate Professor, Department of Pharmacy Practice and Science; Assistant Dean for Research, College of Pharmacy, University of KY*
- 11:15 am**                    **LATE: What It Is, Why It's Important, and How We Might Beat It**
- Peter Nelson, MD, PHD *Professor & Director of Neuropathology, Department of Pathology and Laboratory Medicine; Neuropathology Core Director, UK Alzheimer's Disease Research Center; Associate Director, Sanders-Brown Center on Aging*
- 11:30 am**                    **Ask the Experts:**
- Greg Jicha, MD, PhD, *Professor & Vice Chair of Academic Affairs, Department of Neurology; Associate Director & Clinical Core Director, UK Alzheimer's Disease Research Center; Director, Alzheimer's Disease Research Center Clinical Trials Unit; Associate Director, Sanders-Brown Center on Aging*
- Daniela Moga, MD, PhD & Peter Nelson, MD, PhD**
- Keynote Speaker* Maria Carrillo, PhD
- Moderator: Donna Wilcock, PhD, Professor Department of Physiology, Biomarker Core Director, UK Alzheimer's Disease Research Center; Associate Director, Sanders-Brown Center on Aging*
- 12:25 pm**                    **Closing Remarks** Linda Van Eldik, PhD

## Keynote Speaker

### Advancing the Science: The Latest in Alzheimer's and Dementia Research



**MARIA CARRILLO, PHD**  
**Chief Science Officer**  
**National Alzheimer's Association**

As chief science officer, Maria C. Carrillo, Ph.D., sets the strategic vision for the Alzheimer's Association global research program. Under her leadership, the Association is the world's largest nonprofit funder of Alzheimer's research — investing more than \$455 million since 1982 — and an internationally recognized pioneer in convening the dementia science community. Dr. Carrillo uses her platform as a noted public speaker to play an instrumental role in the Association's efforts to lobby for increased funding for the disease.

Dr. Carrillo oversees the implementation of the Association's growing portfolio of research initiatives, including the Alzheimer's Association International Conference® (AAIC®), the world's largest and most influential dementia science meeting, and the Research Roundtable, which enables international scientific, industry and

government leaders to work together to overcome shared obstacles in Alzheimer's science and drug development. In addition, she leads the Association's direct involvement in research by serving as a co-primary investigator for the Association-funded and led U.S. POINTER study, a lifestyle intervention trial to prevent cognitive decline and dementia. Dr. Carrillo earned her Ph.D. from Northwestern University's Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer's brain imaging and risk factors at Rush University Medical Center in Chicago.

*The Alzheimer's Association is the leading voluntary health organization in Alzheimer's care, support and research. Our mission is to eliminate Alzheimer's disease through the advancement of research, to provide and enhance care and support for all affected, and to reduce the risk of dementia through the promotion of brain health. Our vision is a world without Alzheimer's. For more information, visit [alz.org](http://alz.org).*




#### **My Medications and Why Should I Know about Them**

**DANIELA MOGA, MD, PHD**

Dr. Daniela Moga currently serves as Assistant Dean for Research in the College of Pharmacy. Dr. Moga is an Associate Professor in the Department of Pharmacy Practice and Science, and an affiliated faculty member in the Institute for Pharmaceutical Outcomes & Policy (IPOP). She is also jointly appointed as Associate Professor in the Department of Epidemiology in the College of Public Health, and serves as faculty associate with the Sanders-Brown Center on Aging. Dr. Moga's areas of interest include geriatric pharmacoepidemiology and health outcomes research. Currently, her focus is on evaluating the use and health effects

of potentially inappropriate medications by older adults with multiple comorbid conditions. In addition, Dr. Moga's research aims at developing interventions to deprescribe inappropriate medications and optimize treatment in older adults. Dr. Moga currently serves as PI for a large study evaluating the effect of a patient-centered medication therapy management team intervention aiming to bolster cognitive reserve by increasing medication appropriateness in older adults, "INtervention for Cognitive Reserve Enhancement in delaying the onset of Alzheimer's Symptomatic Expression: The INCREASE study"



## **LATE: What It Is, Why It's Important, and How We Might Beat It**

### **PETER NELSON, MD, PHD**

Peter Nelson received his medical degree and a doctorate in philosophy in Neurobiology, from the University of Chicago Pritzker School of Medicine. He then completed anatomic pathology residency, neuropathology clinical fellowship, and post-doctoral fellowship at the University of Pennsylvania Medical Center, Philadelphia. Nelson is board certified by the American Board of Pathology in Anatomic Pathology and Neuropathology. He is director of neuropathology in the University of Kentucky Department of Pathology and Laboratory Medicine and leads the Neuropathology Core of the University of Kentucky Alzheimer's Disease Research Center.

Dr. Nelson's areas of interest include neuropathology, microRNAs, Alzheimer's disease, hippocampal sclerosis of aging, dementia with Lewy bodies, and other neurodegenerative diseases. Through his research, Dr. Nelson helped spearhead a large team that described a common brain disease that mimics Alzheimer's in causing a lack of memory and difficulty thinking. It was originally thought to be a part of Alzheimer's but is actually different and probably will require its own therapeutic strategies. It has been termed Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE).

### **Ask the Experts Panelist**

#### **GREGORY JICHA, MD, PHD**



Dr. Jicha is a Professor and Vice Chair for Academic Affairs in the Department of Neurology and an Associate Director of Sanders-Brown Center on Aging. Dr. Jicha holds the Robert T & Nyles Y McCowan Endowed Chair in Alzheimer's Research and leads the Clinical Core of the UK NIA-funded Alzheimer's Disease Center. He also serves as the Medical Director of KY Telecare and directs the Telemedicine Cognitive Clinic at UK, designed to reach out to rural populations across KY for both clinical and research-related activities in the area of AD and related disorders.

He is the principal investigator at UK for the National Alzheimer's Disease Cooperative Study Group, the Alzheimer's Clinical Trial Consortium, and serves on the Clinical Task Force and Steering Committee for the National Institute of Aging Alzheimer's Disease Center Program. His current research interests are preclinical disease states of dementia, mild cognitive impairment, vascular contributions to dementia, and clinical trials of disease modifying therapies for degenerative dementias.

#### **DONNA WILCOCK, PHD Panel Moderator**



Donna M. Wilcock, PhD is the Sweeney-Nelms Professor in Alzheimer's Disease Research, and an Associate Director at the Sanders-Brown Center on Aging. She is also a Professor with tenure in the Department of Physiology at the University of Kentucky. Dr. Wilcock's research is focused on vascular cognitive impairment and dementia (VCID) and Alzheimer's disease, particularly how these two brain diseases impact one another. VCID is the second most common cause of dementia behind Alzheimer's disease. In addition to being a major cause of dementia, Alzheimer's disease patients commonly have VCID as a co-morbidity. Her research focuses on the molecular mechanisms of VCID, as well as developing clinical biomarkers that will help with diagnosis and, ultimately, treatment. In addition to her work on VCID biomarker discovery, Dr. Wilcock also leads the University of Kentucky Alzheimer's Disease Research Center Biomarker Core, performing fluid and neuroimaging biomarker assessment in longitudinally followed dementia patients. Dr. Wilcock is an Executive Committee Member of the Greater Kentucky and Southern Indiana Alzheimer's Association Chapter and she serves on the State of Kentucky Alzheimer's Council.

